Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2018 12:41 ET | Source: Lysogene

Lysogene Announces Upcoming Presentations at the 2018 International MPS symposium

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system...
August 01, 2018 10:37 ET | Source: Lysogene

Lysogene Reports Second Quarter Cash Position and Provides Business and Strategic Update

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system...
May 15, 2018 11:45 ET | Source: Lysogene

Lysogene Announces the Nomination of Dr. Ralph Laufer as Chief Scientific Officer and Member of the Executive Team

CAMBRIDGE, Mass. and PARIS, May 15, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS)...
April 24, 2018 02:00 ET | Source: Lysogene

Lysogene Signs Partnership Agreement with Dr. Hervé Moine, Researcher at the IGBMC(1) and the SATT(2) Conectus Alsace, in the Fragile X Syndrome

Development of a gene therapy product for the treatment of patients with Fragile X syndromeImplementation of the project through a unique partnershipFirst results anticipated in 2019 ...
April 23, 2018 02:00 ET | Source: Lysogene

Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen

CAMBRIDGE, Mass. and PARIS, April 23, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a leading biopharmaceutical company pioneering gene therapy technologies to treat central nervous system...
April 16, 2018 01:45 ET | Source: Lysogene

Lysogene Reports First Quarter Financial Results and Provides Business Update

Extended CNS pipeline with a collaboration agreement for the development of an AAV-based gene therapy for Fragile X syndrome, the most common single gene cause of autism, a condition of high unmet...
October 04, 2017 04:00 ET | Source: Lysogene

Lysogene Announces Company Presentations at October & November Investor Conferences

PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central...
December 07, 2016 07:00 ET | Source: Lysogene

Lysogene Appoints David Schilansky to Board of Directors

PARIS, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Lysogene, a biopharmaceutical company specializing in gene therapy for rare central nervous system diseases, appointed David Schilansky to the board of...